Glioma cell histone codes are distinct by H3.3K27M mutation status
Using targeted histone mass spectroscopy, we determined histone N-terminal tail signatures (histone codes) in H3.3K27M mutant and wild type (WT) glioma cell lines and astrocytes (Supplementary material 1, Table 1). Histone codes were distinct by H3 mutation status (Fig.1A). K27 di- and tri-methylation (K27me2/3) were significantly decreased in H3.3K27M mutant cells on H3.1 and H.3.3 isoforms (Fig.1A, Supplementary material 2, 3). A significant difference in H3.1K27me3 was also observed, with a mean relative abundance of 15.9% versus 1.4% in mutant versus WT lines (Fig. 1B). A similar trend was observed on H3.3, with H3.3K27me3 relative abundance of 5.6% in H3.3K27 WT cells and only 0.6% in mutants (Fig. 1C). We observed greater K36 di- and tri-methylation in mutants, coupled with less abundant H3.1K36me (Fig.1D, E). H3K79me2 was less abundant in H3.3K27M mutant cells compared to WT (mean= 8.3% and 16.3%, respectively, Fig.1F).
Histone acetylation also differed based on mutation status. Acetylation at H4K16 was lower in H3.3K27 WT cells compared to mutant (31.5% and 48.2%, respectively Fig. 1G). H3.1K27me2 and H3.1K36me2 were the most common PTMs associated with H3.3K27M mutant peptide on multivariate analysis (F=428.7, p<0.01). Importantly, because the H3F3A mutation yielding the H3.3K27M mutant protein is heterozygous, we quantified relative abundance of H3.3K27 WT and H3.3K27M peptides in a given cell sample: 29.2% of H3.3K27 peptides in our mutant cell lines were H3.3K27M (SD=6.6, range 22.2%-35.4%, n=3. Fig. 1C). As expected, the H3.3K27M peptide was not detected in H3.3K27 WT cells.
Glioma tissue histone codes are distinct by H3.3K27M mutation status
Tissue histone PTM profiles also clustered by H3.3K27M mutation status (Fig. 2A). The relative abundance of 16 PTMs were statistically significantly different between H3.3K27M mutant and WT tissues (Supplementary material 4). As with cell lines, the greatest differences in PTMs between H3.3K27M mutant and WT tissues were K27 and K36 methylation states (Fig.2 B-E, Supplementary material 4). We also detected significantly greater acetylation of H2AK5, H4K5, H4K8, H4K12, and H4K16 (Fig. 2F). H3.3K27me1 and H4K16ac were the most common PTM states associated with H3.3K27M peptide abundance on multivariate analysis (F=214.0, p< 0.01).
As the greatest difference in relative abundance of PTM states in H3.3K27M mutant specimens were observed at H3K27, H3K36 and multiple H4 tail amino acids, we queried for the predominant modification states at these residues to determine correlations between specific modification states at these locations (Fig. 3). Overall, K27me1 and K36me2 were the predominant modifications observed on H3.1 and H3.3 isoforms (Fig. 3A), while acetylation was greatest at H4K16 (Fig. 3B). H3.3K36me2 abundance positively correlated with H3.1K36me2 levels, and negatively correlated with H3.3K27me1 (Fig.3C, D). Also, H4K16ac abundance correlated positively with H3.3K36me2, and negatively with H3.3K27me1 (Fig.3E, F).
We also quantified the relative abundance of H3.3K27 WT and H3.3K27M peptides in a given tissue sample. Similar to cell lines, 26.44% of H3.3K27 peptides in our mutant tumor specimens were H3.3K27M (SD=10.7, range 5.2%-44.5%, n=9), with no mutant peptides detected in WT tissues.
Co-occurring histone modification states in tissue specimens
Because our method requires protein digestion for subsequent peptide mass spectrometry, determination of co-occurring PTMs at distant amino acid residues along the N-terminal tail is not possible. However, PTMs at proximal amino acids on the same peptide can be assessed. Therefore, to further explore the relationship between the H3.3K27M mutant peptide and histone PTM states, we investigated the PTMs of H3K27/K36 and H4K5/K8/K12/K16 peptides. The relative abundance of ten combinations of PTM states along these peptides were significantly different by tissue H3.3K27M mutation status (Fig. 4A, Supplementary material 5). Of these, H3.1K27me1K36me2, H3.3K27MK36me2, and H4K5unK8acK12unK16ac were increased in mutants compared to WT. These findings are consistent with the single amino acid analysis presented above (Fig. 2, Supplementary material 4). Further, we observed a positive correlation between H3.1K27me1K36me2 and H3.3K27M peptide abundance, and a negative correlation between H3.1K27me1K36me3 and H3.3K27M peptide abundance (Fig. 4B, 4C, Supplementary material 5). The abundance of the H4K5unK8acK12unK16ac peptide also positively correlated with H3.3K27M peptide abundance (Fig. 4D, Supplementary material 5). In contrast, H3.1K27me2K36me1, H3.1K27me3K36me1, H3.3K27me1K36me2/3 and H3.3K27me2K36me1 peptide abundance negatively correlated with H3.3K27M abundance (Supplementary material 5). On multivariate analysis, K36me2/3 were the most common modification states on the mutant H3.3K27MK36 peptide (F=18444.8, p<0.01). As such, H3.3K27MK36me2 and H3.3K27MK36me3 peptide abundance also positively correlated with H3.3K27M abundance (Fig. 4E, F, Supplementary material 5). Importantly, di-methylation was the predominant modification state of the K36 residue on the H3.3K27MK36 peptide, while K36Ac was least abundant (Fig. 4G).
Radiation treatment alters DIPG histone codes in vitro
As radiation treatment (RT) is the standard therapy for DIPG, we examined the effects of RT on the glioma histone code in vitro. We treated H3.3K27M mutant DIPG cells (SF8628, DIPG007), H3.3K27 WT glioma cells (U87) and normal astrocytes (NHA) with 9 Gy radiation, and performed targeted histone mass spectrometry at 24 and 48 hours post-treatment. Cell histone codes clustered first by origin, then by treatment condition (Fig. 5A). Comparative analysis revealed distinct differences in relative peptide abundance after RT, most notably in acetylated peptides (Supplementary material 6). In DIPG007 cells, the relative abundance of H2AK5ac decreased with RT at 48 hours (Fig. 5B). In contrast, H2AK5ac abundance increased in NHA at 24 and 48 hours, with no significant change in SF8628 or U87 (Fig. 5B). At 24 and 48 hours post-RT, all lines except DIPG007 showed a significant increase in H4K16ac (Fig. 5C, Supplementary material 6). H3K9me3 also significantly increased in NHA, U87, and DIPG007, and trended towards a significant increase in SF8628, after RT (Fig. 5D, Supplementary material 6).
Bromodomain inhibition alters DIPG histone codes in vitro
We previously reported pre-clinical efficacy of JQ1, a BET/Bromodomain inhibitor (BRDi), in DIPG . We observed that BRD proteins are enriched at acetylated residues on histone H3 in DIPG cells and animal models, and that JQ1 treatment results in decreased global H3K27ac, with restoration of global H3K27 methylation . To further elucidate the epigenetic effects of JQ1 in DIPG, we examined its effects on histone codes in SF8628, DIPG007, NHA, and U87 cells. As observed with RT, PTM profiles clustered by cell line, then treatment condition (Supplementary material 7). When analyzed individually, cell profiles cluster by treatment condition (Fig. 6A, Supplementary material 8). In DIPG007 cells, H3.3K27me1 decreased by 1.5% at 48 hours after JQ1 treatment compared to vehicle control, representing the only significant change in modification state observed at that time point (Supplementary material 8). A small increase in H3.3K27M abundance was also detected in DIPG007 at 48 hours (31.4% vs 26.9%, p=0.067, Supplementary material 8). Surprisingly, in DIPG007, H3.3K27ac abundance was not significantly different from control at 48 hours post-treatment, though a marginal decrease was observed at 24 hours (1.65% and 1.95%, respectively, p=0.065, Supplementary material 8).
In contrast, we observed statistically significant differences in abundance of multiple PTMs in SF8628 cells in response to JQ1 (Supplementary material 8). Increased H3.1K27me1 and decreased H3.3K36ac were seen at both 24 hours and 48 hours (Fig. 6B, Table 2, Supplementary material 8). Additional changes in relative modification states were observed after either 24 or 48 hours post-treatment. For example, increased abundance of H3.1/H3.3K27me2, H3.3K36me1, and H4K20me2 were seen 24 hours (Fig. 6B-E, Table 2) and H3K79me2 at 48 hours (Fig. 6F, Table 1, Supplementary material 8). In addition, acetylation of H3K18 significantly decreased at 24 hours (Fig. 6G, Table 2, Supplementary material 8). Surprisingly, we also observed a significant increase in H3.3K27M peptides at 24 and 48 hours after JQ1 treatment in SF8628 cells (Fig. 6B, Table 2, Supplementary material 8).
Changes in histone PTM profiles were also observed in H3.3K27 WT cell lines after exposure to JQ1. The relative abundance of multiple PTMs were observed in U87 cells, including H3.1K27me2/me3, H3.1K36me1/me3, H3.3K36me1/ac, H3K14ac, H3K79me1, H3K4me1, and H4K5ac (Table 3, Supplementary material 8). Lastly, distinct changes were observed in NHAs after JQ1 treatment, including methylation of H3.1K27, H3.1/3.3K36, and H3K79me1, and acetylation of H2AK5, H3.3K36, H3K18, and H4K16ac (Table 4, Supplementary material 8).